Skip to main content

Two medicines, side by side

Baclofen vs cyclobenzaprine

Baclofen and cyclobenzaprine are both labeled for muscle spasms and spasticity. Drugs@FDA records approvals of baclofen since 1977 and of cyclobenzaprine since 1977. Pharmacies paid $0.032 per baclofen 10 mg tablet and $0.0171 per cyclobenzaprine 10 mg tablet (NADAC, October 7, 2026). Cyclobenzaprine's other strengths are brand-only: $29.61 per tablet (Tonmya 2.8 mg tablet sl). In FDA's classes, baclofen is a gamma-aminobutyric acid-ergic agonist and cyclobenzaprine a muscle relaxant.

Check it at the source: the baclofen FDA label on DailyMed (effective August 12, 2024); the cyclobenzaprine FDA label on DailyMed (effective February 21, 2025).

Highlights of the baclofen record

Baclofen (Gablofen) · label of August 12, 2024

Used for

From the label: indications

Baclofen tablets USP are useful for the alleviation of signs and symptoms of spasticity resulting from multiple sclerosis, particularly for the relief of flexor spasms and concomitant pain, clonus, and muscular rigidity. Patients should have reversible spasticity so that baclofen treatment will aid in restoring residual function. […]

On the market

Earliest approval on file
November 22, 1977
Generic labelers
55 labelers
Pharmacy cost
$0.032 per tablet

Supply and safety

Shortage
No current entry
Recalls
3

Highlights of the cyclobenzaprine record

Cyclobenzaprine (Flexeril) · label of February 21, 2025

Used for

From the label: indications

Cyclobenzaprine hydrochloride tablets, USP are indicated as an adjunct to rest and physical therapy for relief of muscle spasm associated with acute, painful musculoskeletal conditions. Improvement is manifested by relief of muscle spasm and its associated signs and symptoms, namely, pain, tenderness, limitation of motion, and restriction in activities of daily living. […]

On the market

Earliest approval on file
August 26, 1977
Generic labelers
59 labelers
Pharmacy cost
$0.0171 per tablet

Supply and safety

Shortage
No current entry
Recalls
5

Source: FDA drug labels via openFDA (Baclofen label of August 12, 2024, Cyclobenzaprine label of February 21, 2025); NDC Directory, Drugs@FDA, NADAC, FDA shortages and recalls (October 8, 2026)

How do baclofen and cyclobenzaprine differ on the record?

In FDA's classes, baclofen is a gamma-aminobutyric acid-ergic agonist and cyclobenzaprine a muscle relaxant.

Generics: baclofen since 1988; cyclobenzaprine since 1988 (Drugs@FDA).

BaclofenCyclobenzaprine
Labeled forMuscle spasms and spasticityMuscle spasms and spasticity, Nerve pain and fibromyalgia
Pharmacologic classgamma-Aminobutyric Acid-ergic AgonistMuscle Relaxant
How it works (label)n/an/a
Half-life (label)n/aCyclobenzaprine is eliminated quite slowly, with an effective half-life of 18 hours (range 8 to 37 hours; n=18); plasma clearance is 0.7 L/min.
Earliest approval on file (Drugs@FDA)November 22, 1977August 26, 1977
First generic approvedJuly 21, 1988February 29, 1988
Generic labelers (NDC)55 labelers59 labelers
Pharmacy cost (NADAC, each one's most listed form; strengths differ)$0.032 per tablet (Baclofen 10 mg tablet)$0.0171 per tablet (Cyclobenzaprine 10 mg tablet)
12-month price change-12%-10%
Boxed warningNoNo
Shortage nowNo current entryNo current entry
Recalls recorded35
FAERS reports (a report is not proof of cause; counts follow how widely a medicine is used)88,35150,442
DEA schedulenonenone

Source: Drugs@FDA, FDA NDC Directory, CMS NADAC of October 7, 2026, FDA shortages and recalls, FAERS via openFDA (FDA files October 8, 2026)

What do the labels say about using others of their kind?

Cyclobenzaprine label, warnings

If concomitant treatment with cyclobenzaprine hydrochloride and other serotonergic drugs is clinically warranted, careful observation is advised, particularly during treatment initiation or dose increases (see PRECAUTIONS :

Source: FDA drug labels via openFDA

What next?

Alternatives to baclofen
every medicine labeled for the same conditions